Effect of conditioned medium of diffuse large B-cell lymphoma cells on proliferation and apoptosis of human bone marrow mesenchymal stem cells

doi:10.12307/2026.524

Abstract

Abstract: BACKGROUND: The relationship between bone marrow microenvironment with growth, survival, and drug resistance of diffuse large B-cell lymphoma has become a hot topic of research, but the effect of diffuse large B-cell lymphoma cell conditioned medium on bone marrow mesenchymal stem cells has not been reported.
OBJECTIVE: To investigate the effect of cell conditioned medium of diffuse large B-cell lymphoma on proliferation and apoptosis of bone marrow mesenchymal stem cells.
METHODS: Bone marrow mesenchymal stem cells were extracted from bone marrow blood of healthy donors by Ficoll density gradient centrifugation method and purified by adhesion method. Meanwhile, two kinds of diffuse large B-cell lymphoma cell supernatant (SU-DHL-2 and OCI-LY3) were used to prepare conditional culture medium. The cells were grouped according to different media: human bone marrow mesenchymal stem cells in the control group were cultured with L-DMEM only. The human bone marrow mesenchymal stem cells in the CM-SU-DHL-2 and CM-OCI-LY3 groups were cultured with 20% SU-DHL-2 cell conditioned culture medium or 20% OCI-LY3 cell conditioned culture medium and 80% L-DMEM complete culture medium. The proliferation of bone marrow mesenchymal stem cells was observed by CCK-8, EDU and crystal violet staining. The migration of bone marrow mesenchymal stem cells was evaluated by scratch method. The cell cycle and apoptosis of bone marrow mesenchymal stem cells were detected by flow cytometry. The expression levels of P21, P16, Bcl-2, and BTK mRNA and protein were detected by real-time PCR and western blot assay.
RESULTS AND CONCLUSION: (1) Compared with the control group, the conditioned medium of SU-DHL-2 and OCI-LY3 cells could significantly promote the proliferation of bone marrow mesenchymal stem cells (P < 0.05), which might be closely related to the low expression of P21 and P16 proteins (P < 0.05). (2) Compared with the control group, the conditioned medium of SU-DHL-2 and OCI-LY3 cells significantly promoted the migration of bone marrow mesenchymal stem cells (P < 0.05). (3) Compared with the control group, the conditioned medium of SU-DHL-2 and OCI-LY3 cells inhibited the apoptosis of bone marrow mesenchymal stem cells (P < 0.05), which might be closely related to the high expression of Bcl-2 and BTK mRNA and protein (P < 0.05). The results showed that the conditioned medium of diffuse large B-cell lymphoma cells could promote the proliferation and inhibit apoptosis of bone marrow mesenchymal stem cells.

Key words: diffuse large B-cell lymphoma, bone marrow mesenchymal stem cell, conditioned medium, proliferation, apoptosis, engineered stem cell

CLC Number:

Yuan Xiaoshuang, Yang Xu, Yang Bo, Chen Xiaoxu, Tian Ting, Wang Feiqing, Li Yanju, Liu Yang, Yang Wenxiu. Effect of conditioned medium of diffuse large B-cell lymphoma cells on proliferation and apoptosis of human bone marrow mesenchymal stem cells [J]. Chinese Journal of Tissue Engineering Research, 2026, 30(7): 1632-1640.

Figures/Tables 2

References

[1] SIEGEL RL, MILLER KD, FUCHS HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7-33.
[2] HU W, ZANG L, FENG X, et al. Advances in epigenetic therapies for B-cell non-hodgkin lymphoma. Ann Hematol. 2024;103(12):5085-5101.
[3] TILLY H, MORSCHHAUSER F, SEHN LH, et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N Engl J Med. 2022;386(4):351-363.
[4] HUNG YS, HUNG CY, CHOU WC. Evaluating the cancer aging and research group model in predicting immunochemotherapy toxicity among elderly patients with diffuse large B-cell lymphoma. Int Immunopharmacol. 2024;138:112544.
[5] SEHN LH, HERRERA AF, FLOWERS CR, et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2020;38(2):155-165.
[6] WU H, ZOU L, JIN Y, et al. Rituximab induces ferroptosis and RSL3 overcomes rituximab resistance in diffuse large B-cell lymphoma cells. Arch Biochem Biophys. 2024;761:110188.
[7] KUSOWSKA A, KUBACZ M, KRAWCZYK M, et al. Molecular Aspects of Resistance to Immunotherapies-Advances in Understanding and Management of Diffuse Large B-Cell Lymphoma. Int J Mol Sci. 2022;23(3):1501.
[8] DUMONTET E, MANCINI SJC, TARTE K. Bone Marrow Lymphoid Niche Adaptation to Mature B Cell Neoplasms. Front Immunol. 2021;12: 784691.
[9] ZAMÒ A, JOHNSTON P, ATTYGALLE AD, et al. Aggressive B-cell lymphomas with a primary bone marrow presentation. Histopathology. 2020;77(3):369-379.
[10] BOGUN L, KOCH A, SCHERER B, et al. Overlapping Stromal Alterations in Myeloid and Lymphoid Neoplasms. Cancers (Basel). 2024;16(11):2071.
[11] SALAME N, BIKORIMANA JP, EL-HACHEM N, et al. UM171A-induced ROS promote antigen cross-presentation of immunogenic peptides by bone marrow-derived mesenchymal stromal cells. Stem Cell Res Ther. 2022;13(1):16.
[12] DUMONTET E, PANGAULT C, ROULOIS D, et al. Extracellular vesicles shed by follicular lymphoma B cells promote polarization of the bone marrow stromal cell niche. Blood. 2021;138(1):57-70.
[13] PETINATI NA, BIGILDEEV AE, KARPENKO DS, et al. Humoral Effect of a B-Cell Tumor on the Bone Marrow Multipotent Mesenchymal Stromal Cells. Biochemistry (Mosc). 2021;86(2):207-216.
[14] CHAI M, SU G, CHEN W, et al. Effects of Bone Marrow Mesenchymal Stem Cell-Derived Exosomes in Central Nervous System Diseases. Mol Neurobiol. 2024;61(10):7481-7499.
[15] RADTKE AJ, ROSCHEWSKI M. The follicular lymphoma tumor microenvironment at single-cell and spatial resolution. Blood. 2024; 143(12):1069-1079.
[16] LI M, ZHAI P, MU X, et al. Hypoxic BMSC-derived exosomal miR-652-3p promotes proliferation and metastasis of hepatocarcinoma cancer cells via targeting TNRC6A. Aging (Albany NY). 2023;15(22): 12780-12793.
[17] CAO Y, XU P, SHEN Y, et al. Exosomes and cancer immunotherapy: A review of recent cancer research. Front Oncol. 2023;12:1118101.
[18] SIRCAR A, CHOWDHURY SM, HART A, et al. Impact and Intricacies of Bone Marrow Microenvironment in B-cell Lymphomas: From Biology to Therapy. Int J Mol Sci. 2020;21(3):904.
[19] GOODARZI A, VALIKHANI M, AMIRI F, et al. The mechanisms of mutual relationship between malignant hematologic cells and mesenchymal stem cells: Does it contradict the nursing role of mesenchymal stem cells? Cell Commun Signal. 2022;20(1):21.
[20] DOMINICI M, LE BLANC K, MUELLER I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317.
[21] WENIGER MA, SEIFERT M, KÜPPERS R. B Cell Differentiation and the Origin and Pathogenesis of Human B Cell Lymphomas. Methods Mol Biol. 2025;2865:1-30.
[22] YE S, YING W, LIN Y, et al. LncRNA OR2A1-AS1 index predicts survival in germinal center-like diffuse large B-cell lymphoma. J Clin Lab Anal. 2022;36(10):e24680.
[23] CARVALHO AS, BAETA H, HENRIQUES AFA, et al. Proteomic Landscape of Extracellular Vesicles for Diffuse Large B-Cell Lymphoma Subtyping. Int J Mol Sci. 2021;22(20):11004.
[24] PIROSA MC, STATHIS A, ZUCCA E. Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma. Hum Vaccin Immunother. 2024;20(1):2309701.
[25] MARTIN-MORO F, LOPEZ-JIMENEZ J, GARCIA-MARCO JA, et al. Comparative Review of the Current and Future Strategies to Evaluate Bone Marrow Infiltration at Diffuse Large B-Cell Lymphoma Diagnosis. Diagnostics (Basel). 2024;14(6):658.
[26] DOMA A, STUDEN A, JEZERŠEK NOVAKOVIĆ B. The Impact of Bone Marrow Involvement on Prognosis in Diffuse Large B-Cell Lymphoma: An 18F-FDG PET/CT Volumetric Segmentation Study. Cancers (Basel). 2024;16(22):3762.
[27] ZUO H, XIE X, SUN X, et al. Prognostic impact of concordant and discordant bone marrow involvement on diffuse large B-cell lymphoma. Transl Cancer Res. 2024;13(10):5339-5346.
[28] WEN HJ, ZHU SY, YANG HG, et al. Investigation on the molecular mechanism of SPA interference with osteogenic differentiation of bone marrow mesenchymal stem cells. Sci Rep. 2024;14(1):15600.
[29] STONE AP, RAND E, THORNES G, et al. Extracellular matrices of stromal cell subtypes regulate phenotype and contribute to the stromal microenvironment in vivo. Stem Cell Res Ther. 2024;15(1):178.
[30] VERYASKINA YA, TITOV SE, KOVYNEV IB, et al. MicroRNA Expression Profile in Bone Marrow and Lymph Nodes in B-Cell Lymphomas. Int J Mol Sci. 2023;24(20):15082.
[31] AMIRPOUR M, KUHESTANI-DEHAGHI B, KHEYRANDISH S, et al. The impact of exosomes derived from B-cell acute lymphoblastic leukemia as a growth factor on bone marrow mesenchymal stromal cells. Mol Biol Rep. 2024;51(1):749.
[32] BINDER M, SZALAT RE, TALLURI S, et al. Bone marrow stromal cells induce chromatin remodeling in multiple myeloma cells leading to transcriptional changes. Nat Commun. 2024;15(1):4139.
[33] LIU Z, LIU H, LI Y, et al. Multiple myeloma-derived exosomes inhibit osteoblastic differentiation and improve IL-6 secretion of BMSCs from multiple myeloma. J Investig Med. 2020;68(1):45-51.
[34] ALLEGRA A, DI GIOACCHINO M, TONACCI A, et al. Multiple Myeloma Cell-Derived Exosomes: Implications on Tumorigenesis, Diagnosis, Prognosis and Therapeutic Strategies. Cells. 2021;10(11):2865.
[35] WANG J, PANY, WAN Y, et al. SENEX gene promotes cell proliferation by activating RB/E2F pathway in diffuse large B-cell lymphoma cells. Biocell. 2021;45(4):933-942.
[36] SONG W, FEI F, QIAO F, et al. ALKBH5-mediated N6-methyladenosine modification of TRERNA1 promotes DLBCL proliferation via p21 downregulation. Cell Death Discov. 2022;8(1):25.
[37] CZABOTAR PE, LESSENE G, STRASSER A, et al. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2014;15(1):49-63.
[38] SARRO R, BISIG B, GUEY B, et al. Follicular Lymphoma Presenting With Symptomatic Bone Involvement: A Clinicopathologic and Molecular Analysis of 16 Cases. Mod Pathol. 2024;37(4):100440.
[39] TAVAKOLI GM, YAZDANPANAH N, REZAEI N. Targeting Bruton’s tyrosine kinase (BTK) as a signaling pathway in immune-mediated diseases: from molecular mechanisms to leading treatments. Adv Rheumatol. 2024;64(1):61.
[40] JIANG C, SUN C, WANG X, et al. BTK Expression Level Prediction and the High-Grade Glioma Prognosis Using Radiomic Machine Learning Models. J Imaging Inform Med. 2024;37(4):1359-1374.